Physician profile
Michael D Mulock
NPI 1285951228
$16,544.04
in general payments reported to CMS, 2019-2025
47 companies · $1,506 in 2025
The $1,506 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,778 · 2020: $2,081 · 2021: $2,230 · 2022: $2,000 · 2023: $1,710 · 2024: $2,240 · 2025: $1,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,455.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,632.33 | 2019-2025 | Avvigo Guidance System, Rotablator Rotational Atherectomy System Console Kit, Wolverine Coronary Cutting Balloon |
| Cardiovascular Systems INC. | $1,500.89 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $1,426.36 | 2019-2024 | Xarelto |
| Pfizer INC. | $1,240.66 | 2019-2025 | |
| Abbott Laboratories | $1,040.64 | 2019-2025 | Diamondback Coronary, Pressurewire |
| Novartis Pharmaceuticals Corporation | $857.64 | 2019-2025 | |
| Philips North America LLC | $785.04 | 2019-2024 | (Az7) Lasers |
| Amgen INC. | $722.71 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $694.66 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $668.71 | 2019-2025 | Farxiga, Brilinta, Wainua |
| Merck Sharp & Dohme LLC | $611.42 | 2021-2025 | Verquvo, Capvaxive |
| Amarin Pharma, INC. | $585.63 | 2019-2023 | |
| Cvrx, INC. | $524.99 | 2021-2024 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $453.95 | 2021-2025 | |
| Biotronik INC. | $420.46 | 2019-2023 | Biomonitor |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $415.02 | 2019-2025 | Jardiance |
| Tactile Systems Technology INC | $396.55 | 2019-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Veryan Medical Incorporated | $376.11 | 2020-2021 | |
| Irhythm Technologies, INC. | $218.12 | 2024 | Zio Xt Patch, Zio Monitor |
| Daiichi Sankyo INC. | $167.01 | 2023 | Injectafer |
| Endologix LLC | $156.95 | 2025 | |
| Heartflow, INC. | $152.85 | 2024-2025 | |
| Atricure, INC. | $144.70 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $144.56 | 2019-2024 | |
| Medtronic, INC. | $139.95 | 2022 | |
| Abiomed | $124.75 | 2024-2025 | Impella |
| Edwards Lifesciences Corporation | $109.25 | 2022-2025 | Sapien 3 Ultra Resilia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $91.48 | 2019-2025 | Lifevest |
| Esperion Therapeutics, INC. | $81.12 | 2024-2025 | Nexletol |
| Cook Medical LLC | $66.79 | 2020-2021 | |
| Angiodynamics, INC. | $65.75 | 2019-2025 | Auryon Laser System 100-120 Vac |
| Scpharmaceuticals INC. | $63.21 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $59.71 | 2019-2024 | Opsumit |
| Bard Peripheral Vascular, INC. | $57.97 | 2019-2024 | Crosser Iq |
| Alnylam Pharmaceuticals INC. | $42.18 | 2021-2025 | Onpattro |
| Kiniksa Pharmaceuticals, LTD. | $40.43 | 2023 | Arcalyst |
| Novo Nordisk INC | $35.75 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Reprise Biomedical, INC. | $28.10 | 2024 | Miro3d |
| Kerecis Limited | $27.71 | 2021-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Impulse Dynamics (USA) INC. | $26.24 | 2023 | Optimizer |
| Kestra Medical Technology Services, INC. | $24.74 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $23.65 | 2024 | Arcalyst |
| Vifor Pharma, INC. | $22.59 | 2021 | |
| Nevro Corp. | $21.18 | 2023 | Senza |
| Cmp Pharma, INC. | $20.50 | 2020 | |
| Cardiva Medical, INC. | $19.56 | 2020 | |
| Preventice Services, LLC | $13.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mulock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.